Crescita to Distribute
NCTF® and ART
FILLER® Injectables in Canada
LAVAL, QC, Jan. 20, 2020 /PRNewswire/ - Crescita
Therapeutics Inc. (TSX: CTX) and (OTC US: CRRTF) ("Crescita" or the
"Company"), a commercial dermatology company with manufacturing
capabilities and a portfolio of non-prescription skincare products
and prescription drug products for the treatment and care of skin
conditions, diseases and their symptoms, today announced that
it has entered into a distribution agreement (the "Agreement") with
Laboratoires FILLMED (formerly Laboratoires Filorga Medical,
"FILLMED") for the exclusive distribution of the
ART-FILLER® injectables range and New Cellular Treatment
Factor® ("NCTF®") in Canada.
FILLMED is a French aesthetic medicine company with expertise in
developing aesthetic and cosmetic anti-ageing treatment solutions
using hyaluronic acid.
The partnership with FILLMED will allow Crescita to expand its
product offering in the medical aesthetic field with the addition
of the hyaluronic acid ("HA") ART-Filler® injectables range and
NCTF® 135 HA, a skin rejuvenation solution indicated primarily for
the improvement of skin quality and fine lines and a global leader
in its category.
"We are thrilled to have been selected by FILLMED, a
highly-regarded global leader in the medical aesthetic space to
launch and distribute their products in Canada," commented Serge Verreault, Crescita's President and CEO.
"We are excited for the opportunity to expand our medical aesthetic
portfolio in Canada and be the
first to bring these high quality advanced HA serums and
injectables to Canadian practitioners and consumers."
"We are delighted to start this new partnership with Crescita
Therapeutics in Canada. This is
the opportunity for us to expand our activities into North America and offer our high quality
French-made products to Canadian doctors," commented Christophe Foucher, Fillmed's Chief Executive
Officer. "We hope to write, together with Crescita, a successful
new chapter of aesthetic medicine thanks to this
collaboration."
The Company anticipates launching both products on the Canadian
market following approval by Health Canada anticipated by late 2020
or early 2021.
About Crescita Therapeutics Inc.
Crescita (TSX: CTX
and OTC US: CRRTF) is a publicly traded, Canadian commercial
dermatology company with manufacturing capabilities and a portfolio
of non-prescription skincare products for the treatment and care of
skin conditions, diseases and their symptoms and prescription drug
products for the treatment of pain. Crescita owns multiple
proprietary drug delivery platforms that support the development of
patented formulations that can facilitate the delivery of active
drugs into or through the skin.
Supported by a sales force covering Canada and executing its business to business
to consumer marketing approach, Crescita sells its non-prescription
products through spas, medispas and medical clinics. In addition,
our brands and formulations are currently sold in the U.S. and
certain Asian markets through international distributors as well as
through a leading cross-border e-commerce channel in China.
Crescita developed a prescription product called
Pliaglis® that utilizes our proprietary
phase-changing topical cream Peel technology. Pliaglis is a topical
local anaesthetic cream that provides safe and effective local
dermal analgesia on intact skin prior to superficial dermatological
procedures. The product is currently approved in over 25 different
countries and sold by commercial partners in the U.S., Italy and Brazil.
Crescita also provides contract development and manufacturing
services to several local and North American clients. Our contract
development and manufacturing organization infrastructure allows
Crescita to provide its clients with development and other support
activities required to bring their products to market. Crescita has
extensive expertise in product formulation and development,
leveraging our patented transdermal delivery technologies, and
specializes in manufacturing creams, liquids, gels ointments and
serums. The Company operates out of a 50,000 square-foot
manufacturing facility located in Laval, Québec that is compliant with current
Canadian Good Manufacturing Practices and is regularly inspected by
Health Canada.
About Filorga/FILLMED
FILLMED has designed,
developed and marketed anti-aging products for aesthetic medicine
professionals since 1978: for surgeons, dermatologists and
aesthetic medicine practitioners. These products correct the signs
of aging and improve skin quality. Over the years,
NCTF® and ART FILLER® injectables ranges have become
benchmark products for both practitioners and patients. They are
distributed extensively in more than 60 different countries across
the globe.
About NCTF® 135 HA
FILLMED NCTF® 135
HA is an injectable solution indicated for the rejuvenation of
the skin, improvement of skin quality and fine lines. Since 1978,
NCTF® (New Cellular Treatment Factor®) has been the undisputed
leader in skin rejuvenation with over 3 million bottles sold in
more than 50 countries. Comprising hyaluronic acid and revitalizing
ingredients, NCTF® 135 HA is a hydration booster providing the
essential ingredients for skin health. It slows and corrects
age-related skin changes: dryness, dullness, uneven complexion,
dilated pores and wrinkles.
About ART-FILLER®
ART FILLER® is an exclusive
collection of 4 hyaluronic acid-based fillers designed to smooth
out superficial-to-deep wrinkles, plump up the lips and
create/restore the volumes and contours of the face. Each product
of the range has been developed bearing in mind a precise treatment
objective, thanks to four optimized textures tailored to match each
injection site.
Developed, manufactured and launched in 2016 by Laboratoires
FILLMED, the ART FILLER® range benefits from an innovation in
R&D: the Tri-Hyal® technology. Made of non-animal origin
hyaluronic acid, the gels feature a perfect equilibrium between
free hyaluronic acid, long chains and very long chains hyaluronic
acid. For an optimal injection experience, each product
contains 0.3% lidocaine.
The high performance and the tolerance of ART FILLER® have been
proven over an 18-month period through a unique study combining
clinical evaluations and instrumental-based measurements. The ART
FILLER® collection is to the practitioner what the palette is to an
artist: a way to express his art.
Forward-Looking Information Cautionary Statement
This
press release contains "forward-looking information" as defined
under Canadian securities laws (collectively, "forward-looking
statements"). The words "plans", "expects", "does not expect",
"goals", "seek", "strategy", "future", "estimates", "intends",
"anticipates", "does not anticipate", "projected", "believes" or
variations of such words and phrases or statements to the effect
that certain actions, events or results "may", "will", "could",
"would", "should", "might", "likely", "occur", "be achieved" or
"continue" and similar expressions identify forward-looking
statements. In addition, any statements that refer to expectations,
intentions, projections or other characterizations of future events
or circumstances contain forward-looking statements.
Forward-looking statements are not historical facts but instead
represent management's expectations, estimates, projections and
assumptions regarding future events or circumstances. Such
forward-looking statements are qualified in their entirety by the
inherent risks, uncertainties and changes in circumstances
surrounding future expectations which are difficult to predict and
many of which are beyond the control of the Company.
Forward-looking statements are necessarily based on a number of
estimates and assumptions that, while considered reasonable by
management of the Company as of the date of this press release, are
inherently subject to significant business, economic and
competitive uncertainties and contingencies. Material factors and
assumptions used to develop the forward-looking statements, and
material risk factors that could cause actual results to differ
materially from the forward-looking statements, include but are not
limited to changes in the business or affairs of Crescita; the
ability of Crescita's licensees to successfully market its
products; competitive factors in the industries in which Crescita
operates; relationships with customers, suppliers and licensees;
changes in legal and regulatory requirements; foreign exchange and
interest rates; prevailing economic conditions; and other factors,
many of which are beyond the control of Crescita.
Additional factors that could cause Crescita's actual results
and financial condition to differ materially from those indicated
in the forward-looking statements include, among others, the risk
factors included in Crescita's most recent Annual Information Form
dated March 18, 2019 under the heading "Risks Factors",
and as described from time to time in the reports and disclosure
documents filed by Crescita with Canadian securities regulatory
agencies and commissions. These and other factors should be
considered carefully, and readers should not place undue reliance
on Crescita's forward-looking statements, as forward-looking
statements involve significant risks and uncertainties.
Forward-looking statements should not be read as guarantees of
future performance or results and will not necessarily be accurate
indications of whether or not the times at or by which such
performance or results will be achieved.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/crescita-signs-exclusive-distribution-agreement-with-fillmed-300989565.html
SOURCE Crescita Therapeutics Inc.